PEEK Versus Silicon Interspinous Spacer for Reduction of Supradjacent Segment Degeneration

NCT ID: NCT03477955

Last Updated: 2018-04-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-04-30

Study Completion Date

2009-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A retrospective study that aims to report Adjacent Segment Degeneration (ASD) incidence and spinopelvic balance in short lumbosacral instrumentation for degenerative lumbar spinal stenosis. Although ASD is a common complication following lumbar fusion, the effect of an Interspinous Spacer (IS) in the supradjacent segment in short lumbosacral instrumented fusion and its interaction with spinopelvic balance has not been studied adequately.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Methods From 55 consecutive age-, diagnosis- and gender- matched patients aged 60±11 years, 17 (Group R) received PEEK IS; 18 (Group S) received Silicon IS and compared with 20 controls (Group C) without receiving any IS. The functional outcome was evaluated with VAS and ODI. Spinopelvic balance was evaluated using SVA, T12-S1 LL, SS, PT, PI and supradjacent segment disc heights. All spines were preoperatively balanced.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adjacent Segment Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Peek Group

Patients that received PEEK interspinous spacer

Group Type ACTIVE_COMPARATOR

PEEK interspinous spacer

Intervention Type PROCEDURE

To study the Adjacent Segment Degeneration incidence in the supradjacent segment following short lumbar fusion between PEEK and Silicon Interspinous spacers.

Silicon Group

Patients that received Silicon interspinous spacer and did not receive PEEK interspinous spacer

Group Type ACTIVE_COMPARATOR

PEEK interspinous spacer

Intervention Type PROCEDURE

To study the Adjacent Segment Degeneration incidence in the supradjacent segment following short lumbar fusion between PEEK and Silicon Interspinous spacers.

Control Group

Patients that did not receive PEEK interspinous spacer nor Silicon interspinous spacer

Group Type ACTIVE_COMPARATOR

PEEK interspinous spacer

Intervention Type PROCEDURE

To study the Adjacent Segment Degeneration incidence in the supradjacent segment following short lumbar fusion between PEEK and Silicon Interspinous spacers.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PEEK interspinous spacer

To study the Adjacent Segment Degeneration incidence in the supradjacent segment following short lumbar fusion between PEEK and Silicon Interspinous spacers.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Silicon interspinous spacer

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Preoperative MRI with degeneration grades\<III at the 1st supradjacent lumbar segment.

Exclusion Criteria

* Body mass index≥40kg/m\*m
* Severe osteoporosis
* Lumbar fracture
* Preoperative SVA\>4cm
* Spondylolisthesis grades\>II or spondylolytic lesion and acquired spinous process insufficiency in the supradjacent segment cephalad to instrumentation
Minimum Eligible Age

49 Years

Maximum Eligible Age

71 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

St. Andrew's General Hospital, Patras, Greece

OTHER

Sponsor Role collaborator

University Hospital of Patras

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Vasileios Syrimpeis

Orthopaedic Surgeon

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Panagiotis Korovessis, PhD

Role: PRINCIPAL_INVESTIGATOR

General Hospital of Patras

References

Explore related publications, articles, or registry entries linked to this study.

Korovessis P, Syrimpeis V, Tsekouras V, Vardakastanis K, Fennema P. PEEK versus Silicon Interspinous Spacer for Reduction of Supradjacent Segment Degeneration following Decompression and Short-Segment Instrumentation for Degenerative Lumbar Spinal Stenosis. Adv Orthop. 2018 Aug 8;2018:1623647. doi: 10.1155/2018/1623647. eCollection 2018.

Reference Type DERIVED
PMID: 30174959 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

WALLIS2018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Fusion Status After ACDF
NCT05986006 UNKNOWN NA